Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
2(22%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_2
4
44%
Ph phase_3
1
11%
Ph phase_4
4
44%

Phase Distribution

0

Early Stage

4

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 2Efficacy & side effects
4(44.4%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
4(44.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(3)
Completed(5)
Terminated(1)

Detailed Status

Completed5
Active, not recruiting2
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 24 (44.4%)
Phase 31 (11.1%)
Phase 44 (44.4%)

Trials by Status

completed556%
active_not_recruiting222%
not_yet_recruiting111%
withdrawn111%

Recent Activity

2 active trials
Showing 5 of 9
active_not_recruitingphase_2

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

NCT04414540
completedphase_3

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

NCT06128967
not_yet_recruitingphase_2

Hyperemesis Gravidarum Risk Reduction With Metformin

NCT07129473
completedphase_2

A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.

NCT05571319
completedphase_2

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

NCT04409795
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT04414540Phase 2

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

Active Not Recruiting
NCT06128967Phase 3

A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Completed
NCT07129473Phase 2

Hyperemesis Gravidarum Risk Reduction With Metformin

Not Yet Recruiting
NCT05571319Phase 2

A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.

Completed
NCT04409795Phase 2

Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study

Completed
NCT05317806Phase 4

Metformin Use in Cardiac Fibrosis in PAI-1 Deficiency

Active Not Recruiting
NCT04741204Phase 4

Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer

Withdrawn
NCT03670043Phase 4

Tolerance & Responsiveness Improvement for Metformin (TRIM)

Completed
NCT03467763Phase 4

Trial of an Intervention to Improve Metformin Persistence and Adherence

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9